<DOC>
	<DOCNO>NCT00189696</DOCNO>
	<brief_summary>This study examine efficacy , safety tolerability oral dose YM060 , 5-HT3 receptor antagonist , patient d-IBS .</brief_summary>
	<brief_title>Phase 3 Study YM060 Patients With Diarrhea-predominant Irritable Bowel Syndrome ( d-IBS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Patients satisfy Rome II Diagnostic Criteria . Patients organic change observe large intestine . Patients diseases interfere evaluation efficacy safety study . Patients receive and/or receive prior enrollment treatment interfere evaluation efficacy safety study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Irritable Bowel Syndrome , Diarrhea</keyword>
</DOC>